Biogen Inc. (NASDAQ:BIIB) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Biogen Inc. (NASDAQ:BIIB) have been assigned a consensus rating of “Moderate Buy” from the thirty-one ratings firms that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, twelve have issued a hold recommendation, sixteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $217.4074.

BIIB has been the topic of a number of research analyst reports. UBS Group upgraded Biogen from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $185.00 to $225.00 in a research report on Wednesday, April 22nd. Oppenheimer boosted their price objective on shares of Biogen from $275.00 to $300.00 and gave the stock an “outperform” rating in a research report on Thursday, May 14th. Citigroup raised their target price on shares of Biogen from $190.00 to $200.00 and gave the company a “neutral” rating in a report on Friday, May 1st. The Goldman Sachs Group upped their price target on shares of Biogen from $231.00 to $238.00 and gave the company a “buy” rating in a report on Friday, April 24th. Finally, Truist Financial dropped their price objective on shares of Biogen from $193.00 to $189.00 and set a “hold” rating for the company in a research note on Monday, April 13th.

Biogen Price Performance

BIIB stock opened at $209.74 on Thursday. The firm has a 50 day moving average of $195.49 and a 200-day moving average of $186.53. Biogen has a 12-month low of $121.05 and a 12-month high of $219.72. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. The company has a market cap of $30.97 billion, a price-to-earnings ratio of 22.50 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter in the prior year, the firm posted $3.02 EPS. The company’s revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities analysts expect that Biogen will post 13.95 EPS for the current fiscal year.

Institutional Trading of Biogen

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Rothschild Investment LLC increased its position in Biogen by 12.3% during the 4th quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 56 shares in the last quarter. Meeder Advisory Services Inc. lifted its holdings in Biogen by 1.2% in the 1st quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company’s stock valued at $866,000 after purchasing an additional 57 shares in the last quarter. Kera Capital Partners Inc. boosted its stake in shares of Biogen by 3.5% during the 1st quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company’s stock worth $316,000 after purchasing an additional 58 shares during the last quarter. Parallel Advisors LLC boosted its stake in shares of Biogen by 1.5% during the 1st quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock worth $801,000 after purchasing an additional 65 shares during the last quarter. Finally, Itau Unibanco Holding S.A. grew its holdings in shares of Biogen by 24.4% during the fourth quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock worth $59,000 after buying an additional 66 shares in the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.